NCT06058390View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

May 3, 2024

Study Completion Date

May 3, 2024

Conditions
Hepatitis B
Interventions
DRUG

Bepirovirsen

Bepirovirsen will be administered.

Trial Locations (2)

78744

GSK Investigational Site, Austin

89113

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06058390 - A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants | Biotech Hunter | Biotech Hunter